Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German study group hematology and oncology study

Journal of Clinical Oncology

Volumn 25, Issue 15, 2007, Pages 1986-1992

  Herold, Michael ^a   Haas, Antje ^b   Srock, Stefanie ^b   Neser, Sabine ^b   Al Ali, Kathrin Haifa ^b   Neubauer, Andreas ^b   Dölken, Gottfried ^b   Naumann, Ralph ^b   Knauf, Wolfgang ^b   Freund, Mathias ^b   Rohrberg, Robert ^b   Höffken, Klaus ^b   Franke, Astrid ^b   Ittel, Thomas ^b   Kettner, Erika ^b   Haak, Ursula ^b   Mey, Ulrich ^b   Klinkenstein, Christian ^b   Aßmann, Michael ^b   Von Grünhagen, Ullrich ^b  

^a HELIOS KLINIKUM ERFURT   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; CHLORAMBUCIL; MITOXANTRONE; PREDNISOLONE; RITUXIMAB; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE PAIN; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; INFECTION; INJECTION SITE REACTION; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; STOMATITIS; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADOLESCENT; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; FEMALE; HUMANS; INTERFERON ALFA-2B; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MITOXANTRONE; PREDNISOLONE; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34249939116     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.4618     Document Type: Article

References (33)

1. The Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997
2. Rohatiner AZS, Lister TA: The clinical course of follicular lymphoma. Best Pract Res Clin Haematol 18:1-10, 2005
3. Johnson PWM, Rohatiner AZS, Whelan JS, et al: Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single centre. J Clin Oncol 13:140-147, 1995
4. Lister TA: High-dose therapy for follicular lymphoma revisited: Not if, but when? J Clin Oncol 21:3894-3896, 2003
5. López-Guillermo A, Cabanillas F, McLaughlin P, et al: Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: Update of the MDACC series. Ann Oncol 11:137-140, 2000 (suppl 1)
6. Schouten HC, Qian W, Kvaloy S, et al: High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial. J Clin Oncol 21:3918-3927, 2003
7. Deconinck E, Foussard C, Milpied N, et al: High dose therapy followed by autologous purged stem cell transplantation and doxorubicin based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by the GOELAMS. Blood 105:3817-3823, 2005
8. Reff ME, Carner K, Chambers KS, et al: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445, 1994
9. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
10. Cartron G, Watier H, Golay J, et al: From the bench to the bedside: Ways to improve rituximab efficacy. Blood 104:2635-2642, 2004
11. Demidem A, Lam T, Alas S, et al: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12:177-186, 1997
12. Czuczman MS, Grillo-Lopez AJ, White CA, et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276, 1999
13. Czuczman MS, Weaver R, Alkuzweny B, et al: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 22:4711-4716, 2004
14. Hiddemann W, Kneba M, Dreyling M, et al: Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 106:3725-3732, 2005
15. Wöhrer S, Drach J, Henja M, et al: Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). Ann Oncol 14:1758-1761, 2003
16. Wöhrer S, Raderer M, Kaufmann H, et al: Effective treatment of indolent non-Hodgkin's lymphomas with mitoxantrone, chlorambucil and prednisone. Onkologie 28:73-78, 2005
17. Chow KU, Sommerlad WD, Boehrer S, et al: Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspases. Haematologica 87:33-43, 2002
18. Rose AL, Smith BE, Maloney DG: Glucocorticoids and rituximab in vitro: Synergistic direct antiproliferative and apoptotic effects. Blood 100:1765-1773, 2002
19. National Cancer Institute of Canada Clinical Trial Group: NCIC common toxicity criteria (CTC) grading system, in Cassidy J, Bissett D, Spence R (eds): Oxford Handbook of Oncology. London, United Kingdom, Oxford University Press, 2002
20. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 17:1244, 1999
21. Bennett JM, Moloney WC, Greene MH, et al: Acute myeloid leukemia and other myelopathic disorders following treatment with alkylating agents. Hematol Pathol 1:99-104, 1987
22. McLaughlin P, Estey E, Glassman A, et al: Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, dexamethasone (FND) plus rituximab and interferon alfa. Blood 105:4573-4575, 2005
23. Landys KE: Mitoxantrone in combination with prednimustine in treatment of unfavorable non-Hodgkin lymphoma. Invest New Drugs 6:105-113, 1988
24. Hiddemann W, Unterhalt M, Koch P, et al: Treatment of low-grade non-Hodgkin's lymphoma by cytoreductive chemotherapy with prednimustine/ mitoxantrone followed by interferon alpha-2b maintenance: Results of a clinical phase II study. Semin Oncol 17:20-23, 1990 (suppl 10)
25. Unterhalt M, Herrmann R, Tiemann M, et al: Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma: German Low-Grade Lymphoma Study Group. Leukemia 10:836-843, 1996
26. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005
27. Marcus R, Imrie K, Catalano R, et al: Rituximab plus chemotherapy improves survival in previously untreated patients with advanced follicular non-Hodgkin's-lymphoma. 48th Annual Meeting of the American Society of Hematology, Orlando, FL, December 9-12, 2006 (abstr 481)
28. Salles GA, Foussard C, Mounier N, et al: Rituximab added to alphalFN + CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: First analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients. 46th Annual Meeting of the American Society of Hematology, San Diego, CA, December 4-7, 2004 (abstr 160)
29. Aviles A, Duque G, Talavera A, et al: Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival. Leuk Lymphoma 20:495-499, 1996
30. Hochster HS, Weller E, Gascoyne R, et al: Rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Presented at the 47th Annual Meeting of the American Society of Hematology, Atlanta, GA, December 10-13, 2005
31. Hiddemann W, Forstpointner R, Dreyling M, et al: Rituximab maintenance therapy following a rituximab-containing chemotherapy significantly prolongs the duration of response in patients with relapsed follicular and mantle cell lymphomas: Results of a prospective randomized trial of German Low Grade Lymphoma Study Group (GLSG). Presented at the 46th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005
32. Van Oers MJH, van Glabbeke M, Teodorovic I, et al: Chimeric anti-CD20 monoclonal antibody (rituximab: MabThera) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Final analysis of a phase III Intergroup clinical trial. Presented at the 47th Annual Meeting of the American Society of Hematology, Atlanta, GA, December 10-13, 2005
33. Ghielmini M, Schmitz S-F, Cogliatti SB, et al: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 103:4416-4423, 2004